Loading...
•
Jun 30
ClearPoint Neuro Q2 2025 Earnings Report
ClearPoint Neuro reported record revenue in Q2 2025, driven by strong growth across all business segments and bolstered by a significant cash infusion.
Key Takeaways
ClearPoint Neuro delivered its highest-ever quarterly revenue in Q2 2025, supported by strong demand in neurosurgery and biologics. Despite a net loss, the company’s strategic expansion and strengthened cash position reflect confidence in future growth.
Achieved record revenue of $9.2 million, up 17% YoY
Neurosurgery navigation and therapy revenue grew 33%
Reported operating loss of $5.68 million and net loss of $5.84 million
Cash position increased to $41.5 million following financing deals
ClearPoint Neuro
ClearPoint Neuro
ClearPoint Neuro Revenue by Segment
Revenue by Segment
Biologics and Drug Delivery Revenue
CapyFin.comNeurosurgery Navigation and Therapy Revenue
CapyFin.comCapital Equipment and Software Revenue
CapyFin.com Forward Guidance
ClearPoint reaffirmed its 2025 revenue guidance, projecting continued momentum driven by its growth pillars including laser therapy and expansion into new markets.
Positive Outlook
- Full-year 2025 revenue expected between $36M and $41M
- Growth from laser therapy and SmartFrame OR devices
- Expansion into new operating room and geographic markets
- Increased collaboration with BioPharma partners
- Strong cash position supports future investments
Challenges Ahead
- Gross margin declined to 60% due to higher inventory reserves
- Operating expenses rose 16% YoY
- No positive EPS or profitability in Q2
- R&D and G&A costs increased with headcount
- Service revenue growth modest compared to product revenue
Revenue & Expenses
Visualization of income flow from segment revenue to net income